Alopecia
Conditions
Brief summary
The purpose of this study is to determine if immunophilin ligands may have the potential to reverse hair loss.
Detailed description
Preliminary experiments in C57BL/6J mice showed that immunophilin ligand FK506 and its non-immunosuppressive analogs, GP11046 and GP11511 were capable of promoting telogen to anagen transition. Since GP11046 and GP11511 possess the neurotrophic properties of FK506 without its immunosuppressant capability, the neural action of these immunophilin ligands may play an important role in the hair cycle. This finding has significant clinical implications in that immunophilin ligands may have the potential to reverse alopecia. To further investigate this possibility we propose to explore the response of transplanted miniaturized scalp hair follicles to topically applied immunophilin ligands.
Interventions
DRUGFK506, GP11046, GP11511
Sponsors
Hordinsky, Maria K., MD
Study design
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy men ages 18-65 with Hamilton type IV or V alopecia
Exclusion criteria
* Individuals who do not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The average number of terminal hairs per graft will be compared between the control and the treated group. | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of follicles in anagen, catagen and telogen per graft will be averaged for each group. The results will be compared between the control and the treated groups. | — |
Countries
United States
Outcome results
None listed